Nicolas A. Chronos

TL;DR: A single intracoronary infusion of rFGF2 does not improve exercise tolerance or myocardial perfusion but does show trends toward symptomatic improvement at 90 (but not 180) days.

TL;DR: Percutaneous coronary intervention continues to revolutionize the treatment of coronary atherosclerosis and the examination of neointimal hyperplasia in injured animal artery models has helped in understanding of angioplasty and stenting mechanisms.

TL;DR: The preliminary data suggest that the administration of rFGF-2 to patients with advanced coronary disease resulted in an attenuation of stress-induced ischemia and an improvement in resting myocardial perfusion; these findings are consistent with a favorable effect of therapeutic angiogenesis.

TL;DR: The results suggest that the type of contrast media used during invasive imaging of the vasculature could have a significant effect on platelets, especially within a PTCA-damaged vessel.

TL;DR: Comparison of fibrinogen binding with expression of CD63 antigen on normal platelets, stimulated with agonists in vitro, demonstrated that fibr inogen binding detects an earlier stage of platelet activation.